Relationship between Multiple Forms of Plasminogen Activator in Human Breast Tumors and Plasma and the Presence of Metastases in Lymph Nodes

Marina Colombi, Sergio Barlati, Henri Magdelenat, and Berta Fiszer-Szafarz

Institut Curie-Biologie, Bât. 111, Centre Universitaire, 91405 Orsay, France [M. C., B, F-S.], Istituto di Biologia, Facoltà di Medicina, Università di Brescia, 25100 Brescia, Italy [M. C., S. B.], and Institut Curie, Section Médicale, 26 rue d’Ulm, 75231 Paris, Cedex, France [H. M.]

ABSTRACT

Plasminogen activators (PAs), a family of proteases active in blood coagulation, may play an important role in cancer. Indeed, blood coagulation disorders, such as altered fibrinogen and fibrin metabolism and increased incidence of vascular thrombosis, are common in patients with advanced malignant disease. Different types of human tumors are known to contain high levels of PA. The isoelectric focusing patterns of the PAs present in tumors and plasma from patients with breast cancer were compared with those of purified human urokinase and melanoma tissue PA.

The pattern of isoelectric molecular forms of PA active at pH 8 showed two groups of several bands: in plasma from tumor-bearing patients and controls, these groups were in the pi ranges of 6.6 to 6.8 and 8.0 to 8.5; in mammary adenocarcinoma tissue, the ranges were 6.8 to 7.9 and 9.0 to 9.4. These patterns were different from those obtained with purified markers; the latter were 5.8 to 9.4 and 5.9 to 7.6 for purified human urokinase and melanoma plasminogen tissue activator, respectively. PA activity in tumor-bearing patients was very high in malignant tissue and, on the contrary, very decreased in plasma; this latter decrease was correlated with the presence of metastases in the axillary lymph nodes.

These results suggest that the high PA activity in the tumor tissue might participate in the destruction of the peritumoral tissue, thus allowing its invasion by tumor cells, whereas the low activity of PA in the plasma might increase plasma fibrin, reflecting thus an early disorder in blood coagulation which would enhance the formation of metastases.

INTRODUCTION

PAs constitute a family of proteases which are involved in not only the fibrinolytic cascade but also cancer. Blood coagulation disorders have been known for over 100 years (43) to be common in patients with advanced malignant disease [mainly altered fibrinogen and fibrin metabolism and increased incidence of vascular thrombosis (20, 37)]. Tumor cells enhance platelet aggregation in vitro (17, 18, 22) and display procoagulant activity correlating with their metastatic potential in vivo (19). In vitro transformed cells express higher PA levels than do the normal homologous ones (33, 44); PA synthesis is enhanced by tumor promoters (29, 35) and by conditioned media of transformed cells (23). Different types of human produce high levels of PA (5, 7, 9, 13, 21, 26, 30, 39), but the molecular mechanisms and the role of PA activation in tumor cells are still under investigation (12, 34, 35).

Plasma cryoproteins from cancer patients contain a fraction which displays both PA and transformation-enhancing factor activities (2, 3, 10, 11, 27, 28). The latter activity is probably related to fibronectin degradation fragments produced by the PAs (3, 4).

The metastatic process is a complex sequence of steps that may involve the presence of fibrin and blood coagulation (19). It was therefore of interest to study the types and levels of PAs present in the plasma and in the tumor of patients with mammary adenocarcinomas.

An IEF-CAS technique was developed for the separation and detection of PAs as a function of pi in whole plasma or tumor extracts. Purified human u-PA (24, 40, 45) and t-PA from human melanoma cells (38) were utilized as standards.

The isoelectric forms of PA active at pH 8 separated into 2 groups of several bands. In plasma, these groups were in the pi ranges of 6.6 to 6.8 and 8.0 to 8.5; in tumor tissues, the pi ranges were from 6.8 to 7.9 and 9.0 to 9.4. These patterns were different from those obtained with purified markers; the latter were 5.8 to 9.4 and 5.9 to 7.6 for u-PA and melanoma t-PA, respectively.

PA activity was very high in the tumor tissue; on the contrary, it was very decreased in the plasma. Moreover, a remarkable correlation was found between the decrease of plasma PA activity and the existence of metastases in the axillary lymph nodes.

We suggest that the high PA activity in the tumor tissue might participate in the destruction of the peritumoral tissue, allowing thus the invasion by the tumor, whereas its lack in the plasma of cancer patients would increase plasma fibrin and fibrin deposits, reflecting thus an early disorder in blood coagulation and favoring the formation of metastases.

Some of the preliminary results were presented in poster form at the 13th International Cancer Congress (8).

MATERIALS AND METHODS

Chemicals. Acrylamide, N,N’-methylenebisacrylamide, Trizma base, and human urokinase (EC 3.4.21.31) were purchased from Sigma Chemical Co. (St Louis, MO); agarose (Indubiose A 37) was from IBF (Villemur-la-Garenne, France); ampholines were from LKB (Stockholm, Sweden); 3-dimethylaminopropionitrile was from Eastman Kodak (Rochester, NY).
RESULTS

IEF-CAS Analysis of Purified u-PA and t-PA. Analysis of u-PA shows (Fig. 1) 6 bands of enzymatic activity at pH 8 with pl ranging between 7.2 and 9.4 and a diffuse activity in the pl range of 6.2 to 7.1. IEF-CAS analysis of t-PA at pH 8 reveals 8 bands with pl between 5.9 and 7.6.

The purified u-PA and t-PA tested did not contain any PG-independent caseinolytic activity.

IEF-CAS Analysis of Human Plasma PA. Human plasma from the controls analyzed by IEF-CAS showed various forms of PA activity. Pictures taken after different times of hydrolysis are reported in Fig. 2. At 12 hr, 2 bands with pl of 6.6 and 6.8 are visible, while after 28 hr, a band in the pl range of 8.0 to 8.5 appears. The PA forms with a pl in the range of 4.8 to 5.2 near the site of sample application were not taken into account, since they are probably due to technical artifacts (aggregated enzymes).

Fig. 3 shows the comparison between 2 normal plasmas and 4 plasmas from tumor-bearing patients (2 benign FA and 2 malignant ADC). Control plasma (Lanes 1 and 4) contains PA activity with pl values of 6.6 to 6.8 and to a lesser extent with pl between 8.0 and 8.5. Plasma from FA-bearing patients (Lanes 2 and 5) contains only PA activities with pl values of 6.6 to 6.8. As to plasma from ADC-bearing patients (Lanes 3 and 6), it contains variable PA activity with pl between 6.6 and 6.8 and very weak or no PA activity with pl values of 8.0 to 8.5. A slight caseinolytic activity was observed in the absence of added PG; it was probably due to the low level of PG normally present in human plasma; these forms focused at the same pl range as did the plasma PA forms (36).

Table 1 is a compilation of all cases studied: 38 plasmas from allegedly healthy controls with 6 from FA- and 58 from ADC-bearing patients. It shows that the control plasmas contain high levels of PA activity, the majority being the 4+ and 5+ groups, whereas the plasmas from ADC-bearing patients contain rather lower levels of that activity, most of them being in the range 1+ to 3+. The low number of samples of FA plasmas seems to indicate that they present intermediary levels of PA activity (3+ and 4+).

Table 2 gives evidence for the correlation between the level of PA activity in the plasma of ADC patients and the existence of invaded axillary lymph nodes. It appears quite clearly that the lower the PA activity, the higher the probability of metastases in the lymph nodes.

Table 1

<table>
<thead>
<tr>
<th>Activity rating (total no. of +)</th>
<th>0 1 2 3 4 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls (n = 38)</td>
<td>Kings 5.3 26.3 68.4</td>
</tr>
<tr>
<td>FA (n = 6)</td>
<td>16.7 33.3 33.3 16.7</td>
</tr>
<tr>
<td>ADC (n = 58)</td>
<td>Kings 3.5 34.5 34.5 25.9 1.7</td>
</tr>
</tbody>
</table>

Table 2

<table>
<thead>
<tr>
<th>Plasma PA activity rating (total no. of +)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 1 2 3 4 5</td>
</tr>
<tr>
<td>No. of patients (n = 20) 20 20 15 1 0</td>
</tr>
<tr>
<td>Patients with lymph node metastases (%) 4 10 70.0 45.0 28.7 0</td>
</tr>
</tbody>
</table>
with a high or low pulmonary colonization potential.

The decreased PA activity in cancer plasma might reflect a diminished synthesis of the plasma-type enzyme(s) or the presence of inhibitor(s) (31), which would have to be covalently linked to the enzyme molecule as, in spite of the IEF electrical field, no high activities could be detected. Similarly, hyaluronidase, another hydrolytic enzyme, displays the same pattern; it is very active in the extracellular space of tumors (15), whereas a potent inhibitor is present in the plasma of cancer patients (14).

This decreased PA activity would produce a perturbation in the fibrin metabolism; indeed, a perturbed clotting activity has been described in tumor-bearing patients (20). The thus increased fibrin in plasma could serve as an anchoring for metastatic cells (19).

This loss of plasma PA activity seems to be related to the existence of metastases in axillary lymph nodes, as almost all invaded lymph nodes occur in patients with very low levels of plasma PA activities (Table 2).

Among the allegedly normal plasmas, we observed 2 of them lacking PAs in the 8.0 to 8.5 pi range. We cannot decide whether these plasmas are really normal or express some unknown disease, as we have not studied any other pathology than breast tumor.

We do not know the determinants of the decrease in PA activity of the plasma of cancer patients. However, as this enzyme takes part in the blood coagulation process, the disturbance produced by cancer results in perturbation of that process. This perturbation, in turn, may favor conditions for production and development of metastases.

We have shown that the perturbations in blood coagulation are readily detectable in patients whose tumor has just been discovered.

We have also established a correlation between the decreased PA activity in plasma and the presence of metastases in axillary lymph nodes in mammary cancer patients. The low plasma PA activity in patients with tumors in an early stage of cancer points to the existence of a perturbation of the blood coagulation, which will be greatly amplified in the later stages of the disease (20, 37). We believe that further investigation of this relationship in other types of cancer may throw some light on the mechanism of metastasis and its therapy.

In summary, we suggest that the malignant tumor tissue PA might play a role in the invasion of the peritumoral space, whereas the lack of plasma PA activity facilitates the formation of metastases. The high activity of ADC tissue PA is probably related to the lack of plasma PA activity in the same host by a complex sequence of steps, in which the host reaction is certainly very important.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the help from physicians and scientists from the Curie Hospital and Institute: Dr. J. P. Théry for his financial contribution; many surgeons for providing the plasmas and the surgical tissue specimens; Dr. C. Chieq for histological determinations; Dr. D. Szafarz for very fruitful discussions; and Dr. D. Collen for supplying purified t-PA.

REFERENCES


Table 3
Percentage of distribution of patients according to PA activity in tumor tissue

<table>
<thead>
<tr>
<th>PA activity rating (total no. of +)</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>FA (n = 5)</td>
<td>80</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADC (n = 20)</td>
<td>25</td>
<td>25</td>
<td>30</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IEF-CAS Analysis of Malignant and Benign Breast Tumor Tissue PA. The same analysis of PA was performed on extracts from breast tumors of different histological types. It revealed the presence of 2 different types of PA with pi from 6.8 to 7.9 and from 9.0 to 9.4 (Fig. 4). While the former PA forms were present in malignant and benign tissues, the latter ones were found in malignant tissues only. Table 3 gives a compilation of all the results obtained. It seems that most benign tumors lack any PA activity whatsoever, whereas, on the contrary, malignant tumors are characterized by high levels of all forms of PA.

DISCUSSION

The role of hydrolytic enzymes and particularly proteases in malignant tumor invasiveness and metastasis spreading could be of fundamental importance. Among the many proteases known, PA has been extensively studied in tumor tissue (5, 7, 9, 12, 13, 21, 26, 30, 32–34, 38, 39, 44). We studied this activity in human plasma and breast tumors by IEF-CAS. This technique separates the enzyme activity from possible activators and/or inhibitors. We studied the PA enzymatically active at pH 8.0. Our observations thus do not exclude the possibility of some other forms active at other pHs.

Our results essentially show (a) that the isoelectric patterns of PA forms in human breast tumors (either malignant or benign) are different from those present in the plasma. They also differ from the u-PA and from the melanoma t-PA patterns. This would suggest that the various PA groups observed might be tissue specific, but nevertheless, this does not exclude the possibility that some forms might exist in more than one tissue; however, even if the protein moiety could be the same, it is still very interesting that the presence of different sugar groups could allow plasma PAs to differentiate from the tumor ones; (b) that the malignant tumor tissue groups are very active, whereas the plasma groups from tumor-bearing patients have a very low or no activity at all. The high level of activity of malignant tumor tissue PA is compatible with a role in the spreading of the tumor (42), inasmuch as the benign noninvasive tumors have vanishing levels of PA activity. We found no correlation between the WHO classification of mammary malignant tumors and their level of extractable PA activity. The Scarf-Bloom-Richardson classification of mammary malignant tumors and their level of PA activity were characterized by high levels of all forms of PA.

The role of hydrolytic enzymes and particularly proteases in malignant tumor invasiveness and metastasis spreading could be of fundamental importance. Among the many proteases known, PA has been extensively studied in tumor tissue (5, 7, 9, 12, 13, 21, 26, 30, 32–34, 38, 39, 44). We studied this activity in human plasma and breast tumors by IEF-CAS. This technique yields tissue-specific band patterns corresponding to the various forms of PA; the activity is determined semiquantitatively; it yields tissue-specific band patterns corresponding to the various forms of PA; the activity is determined semiquantitatively; it separates the enzyme activity from possible activators and/or inhibitors. We studied the PA enzymatically active at pH 8.0. Our observations thus do not exclude the possibility of some other forms active at other pHs.

Our results essentially show (a) that the isoelectric patterns of PA forms in human breast tumors (either malignant or benign) are different from those present in the plasma. They also differ from the u-PA and from the melanoma t-PA patterns. This would suggest that the various PA groups observed might be tissue specific, but nevertheless, this does not exclude the possibility that some forms might exist in more than one tissue; however, even if the protein moiety could be the same, it is still very interesting that the presence of different sugar groups could allow plasma PAs to differentiate from the tumor ones; (b) that the malignant tumor tissue groups are very active, whereas the plasma groups from tumor-bearing patients have a very low or no activity at all. The high level of activity of malignant tumor tissue PA is compatible with a role in the spreading of the tumor (42), inasmuch as the benign noninvasive tumors have vanishing levels of PA activity. We found no correlation between the WHO classification of mammary malignant tumors and their level of extractable PA activity. The Scarf-Bloom-Richardson classification of mammary malignant tumors and their level of PA activity were characterized by high levels of all forms of PA.

The role of hydrolytic enzymes and particularly proteases in malignant tumor invasiveness and metastasis spreading could be of fundamental importance. Among the many proteases known, PA has been extensively studied in tumor tissue (5, 7, 9, 12, 13, 21, 26, 30, 32–34, 38, 39, 44). We studied this activity in human plasma and breast tumors by IEF-CAS. This technique yields tissue-specific band patterns corresponding to the various forms of PA; the activity is determined semiquantitatively; it separates the enzyme activity from possible activators and/or inhibitors. We studied the PA enzymatically active at pH 8.0. Our observations thus do not exclude the possibility of some other forms active at other pHs.

Our results essentially show (a) that the isoelectric patterns of PA forms in human breast tumors (either malignant or benign) are different from those present in the plasma. They also differ from the u-PA and from the melanoma t-PA patterns. This would suggest that the various PA groups observed might be tissue specific, but nevertheless, this does not exclude the possibility that some forms might exist in more than one tissue; however, even if the protein moiety could be the same, it is still very interesting that the presence of different sugar groups could allow plasma PAs to differentiate from the tumor ones; (b) that the malignant tumor tissue groups are very active, whereas the plasma groups from tumor-bearing patients have a very low or no activity at all. The high level of activity of malignant tumor tissue PA is compatible with a role in the spreading of the tumor (42), inasmuch as the benign noninvasive tumors have vanishing levels of PA activity. We found no correlation between the WHO classification of mammary malignant tumors and their level of extractable PA activity. The Scarf-Bloom-Richardson classification of mammary malignant tumors and their level of PA activity were characterized by high levels of all forms of PA.
M. Colombi et al.


Fig. 3. PA activity in plasma from tumor-bearing patients. Gels with casein overlay containing 6 μg PG/ml were incubated at pH 8.0 and 37° for 20 hr:

<table>
<thead>
<tr>
<th>Activity level</th>
<th>PI 6.6-6.8</th>
<th>PI 8.0-8.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lane 1, control plasma</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Lane 2, plasma from FA bearer (Case 32)</td>
<td>++</td>
<td>0</td>
</tr>
<tr>
<td>Lane 3, plasma from ADC bearer (Case 73)</td>
<td>+</td>
<td>0</td>
</tr>
<tr>
<td>Lane 4, control plasma</td>
<td>+++</td>
<td>0</td>
</tr>
<tr>
<td>Lane 5, plasma from FA bearer (Case 33)</td>
<td>++</td>
<td>0</td>
</tr>
<tr>
<td>Lane 6, plasma from ADC bearer (Case 88)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Fig. 4. PA activity in extracts of mammary tumors as revealed by IEF. The gels with casein overlay containing 6 μg PG/ml were incubated at pH 8.0 and 37° for 14 hr (a) and 30 hr (b). Lane 1, 6 Sigma milliunits u-PA; Lane 2, extract from FA equivalent to 1 μg DNA or containing 6 μg protein; Lanes 3 and 4, extract from ADC equivalent to 1 μg DNA or containing 6 μg protein.
Relationship between Multiple Forms of Plasminogen Activator in Human Breast Tumors and Plasma and the Presence of Metastases in Lymph Nodes

Marina Colombi, Sergio Barlati, Henri Magdelenat, et al.


Updated version  Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/44/7/2971

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.